Inspire Medical Systems logo
Inspire Medical Systems INSP
$ 50.13 -0.63%

Annual report 2025
added 02-13-2026

report update icon

Inspire Medical Systems Income Statement 2011-2026 | INSP

Annual Income Statement Inspire Medical Systems

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.76 B 5.41 B 5.76 B 7.39 B 6.03 B 5.25 B 1.86 B 752 M - - - - - - -

Shares

29.4 M 29.8 M 29.3 M 28.1 M 27.3 M 26.1 M 23.8 M 14.6 M - - - - - - -

Historical Prices

60 182 197 263 221 202 74.8 53.6 - - - - - - -

Net Income

145 M 53.5 M -21.2 M -44.9 M -42 M -57.2 M -33.2 M -21.8 M -17.5 M -18.5 M -21.3 M - - - -

Revenue

912 M 803 M 625 M 408 M 233 M 115 M 82 M 50.6 M 28.6 M 16.4 M 8.01 M - - - -

Cost of Revenue

133 M 123 M 96.6 M 66.1 M 33.3 M 17.6 M 13.6 M 10.1 M 6.02 M 3.9 M - - - - -

Gross Profit

779 M 680 M 528 M 342 M 200 M 97.8 M 68.4 M 40.5 M 22.5 M 12.5 M 5.2 M - - - -

Operating Income

51 M 36.1 M -40.3 M -47.6 M -39.8 M -56.2 M -34.9 M -20.4 M -16 M -17.3 M - - - - -

Interest Expense

-2.66 M -855 K -195 K -49 K 2.13 M 2.12 M 2.12 M 3.3 M 1.75 M 1.3 M - - - - -

EBITDA

64.9 M 42.6 M -37.4 M -45.7 M -38.6 M -55.4 M -34.4 M -20 M -15.7 M -17.2 M -19.7 M - - - -

Operating Expenses

- - - - 240 M 154 M 103 M 60.9 M 38.6 M 29.8 M 25 M - - - -

General and Administrative Expenses

625 M 530 M 452 M 321 M 203 M 128 M 90.5 M 53.5 M 3.81 M - 2.63 M - - - -

All numbers in USD currency

Quarterly Income Statement Inspire Medical Systems

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

29.3 M 29.5 M 29.7 M 29.7 M 29.9 M 29.7 M 29.6 M 29.6 M 29.4 M 29.2 M 29.1 M 29 M 28.2 M 27.6 M 27.5 M 27.4 M 27.3 M 27.2 M 27.1 M 27.1 M 26.8 M 26.3 M 24.2 M 24.1 M 23.9 M 23.8 M 23.4 M 23.4 M 21.4 M 13.5 M 1.29 M 1.27 M 1.18 M 1.15 M 1.15 M - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

9.93 M -3.59 M 2.99 M - 18.5 M 9.79 M -10 M - -8.54 M -12 M -15.4 M - -16.8 M -14.5 M -16.7 M - -10.3 M -13.1 M -16.2 M -7.48 M -10.4 M -23.1 M -16.2 M -9.08 M -8.25 M -7.65 M -8.27 M -4.78 M -4.69 M -5.86 M -6.5 M -4.25 M -4.02 M -4.76 M -4.48 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

225 M 217 M 201 M - 203 M 196 M 164 M - 153 M 151 M 128 M - 109 M 91.4 M 69.4 M - 61.7 M 53 M 40.4 M 46 M 35.8 M 12.2 M 21.3 M 26.9 M 20.9 M 18 M 16.2 M 16.6 M 13.1 M 10.9 M 10 M 9.96 M 7.27 M 6.04 M 5.3 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

31.8 M 34.7 M 30.7 M - 32.4 M 29.8 M 24.8 M - 24.4 M 24.3 M 19.9 M - 19.8 M 14.2 M 10 M - 8.62 M 7.52 M 5.98 M - 5.21 M 1.95 M 3.3 M - 3.46 M 3.09 M 2.85 M - 2.47 M 2.1 M 2.29 M - 1.56 M 1.38 M 1.2 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

193 M 182 M 171 M - 171 M 166 M 139 M - 129 M 127 M 108 M - 89.4 M 77.2 M 59.4 M - 53.1 M 45.4 M 34.4 M 38.8 M 30.6 M 10.2 M 18 M 22.7 M 17.4 M 14.9 M 13.4 M 13.4 M 10.6 M 8.84 M 7.75 M 8.08 M 5.71 M 4.67 M 4.1 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

9.64 M -3.32 M -1.48 M - 14.3 M 5.1 M -15.2 M - -13.5 M -16.6 M -19.5 M - -17.2 M -14 M -16.1 M - -9.8 M -12.5 M -15.7 M - -9.89 M -22.8 M -16.4 M - -8.65 M -8.18 M -8.78 M - -4.65 M -5.64 M -5.2 M - -3.65 M -4.38 M -4.12 M - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-66 K -3.5 M 578 K - 118 K -135 K -60 K - -224 K -61 K 17 K - 656 K 494 K 527 K - 537 K 530 K 523 K - 533 K 526 K 525 K - 529 K 523 K 537 K - 680 K 550 K 1.38 M - 428 K 4 K -1 K - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

13.3 M 84 K 1.56 M - 16.2 M 6.5 M -14.4 M - -12.7 M -15.9 M -18.9 M - -16.7 M -13.6 M -15.7 M - -8.92 M -12.2 M -15.5 M - -9.3 M -22.4 M -16.3 M - -8.31 M -7.97 M -8.67 M - -4.36 M -5.45 M -5.1 M - -3.48 M -4.28 M -4.08 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - 156 M 161 M 154 M - 142 M 143 M 128 M - 107 M 91.2 M 75.4 M - 62.9 M 58 M 50.1 M - 40.5 M 33 M 34.5 M - 26.1 M 23.1 M 22.2 M - 15.2 M 14.5 M 12.9 M - 9.36 M 9.05 M 8.22 M - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

159 M 160 M 144 M - 130 M 132 M 126 M - 113 M 113 M 102 M - 85.6 M 76.7 M 63.6 M - 53.2 M 48.7 M 41.9 M - 33.2 M 27 M 29.1 M - 22.4 M 20.3 M 19.6 M - 13.5 M 12.7 M 11.2 M - 864 K 801 K 887 K - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Inspire Medical Systems (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.55 -2.31 % $ 73.5 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 88.57 -0.65 % $ 18 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.93 -5.12 % $ 1.64 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.4 4.21 % $ 41.1 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 208.22 -4.53 % $ 14.6 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 34.58 -5.62 % $ 1.07 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.59 -1.18 % $ 32.1 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.15 -5.29 % $ 3.36 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 79.34 -3.36 % $ 46.4 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.2 -1.84 % $ 1.51 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.52 -5.08 % $ 364 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Ra Medical Systems Ra Medical Systems
RMED
- 10.0 % $ 610 K usaUSA
Myomo Myomo
MYO
$ 0.7 2.32 % $ 29.3 M usaUSA
Penumbra Penumbra
PEN
$ 335.1 -0.39 % $ 13 B usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.17 -5.65 % $ 47.6 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
STRATA Skin Sciences STRATA Skin Sciences
SSKN
- - $ 6.6 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 3.82 -1.04 % $ 106 M australiaAustralia
AxoGen AxoGen
AXGN
$ 31.28 -3.01 % $ 1.44 B usaUSA